European radiopharmaceutical startups Nuclidium and Actithera have completed significant financing rounds to advance their platforms. Nuclidium raised approximately $99 million in Series B funding to further clinical development of its copper isotope-based diagnostic and therapeutic agents, addressing drug formulation challenges. Actithera closed a $75.5 million Series A round to develop small-molecule radiopharmaceuticals targeting fibroblast activation protein (FAP), aiming to improve pharmacokinetics and tumor specificity. These financings reflect growing investor interest in radioligand therapy technologies.